EU ADR app to underpin region's regulatory approach to social media

Europe is set to modernize how it conducts some aspects of pharmacovigilance with the launch of a web app in March this year for patients to report adverse drug reactions (ADRs) and a drive to monitor web chatter on the issue. Mick Foy, Group Manager Vigilance Intelligence at the UK’s Medicines and Healthcare products Regulatory Agency, has warned that without progress on the social-media front, manufacturers might shy away from the area to avoid a legal and ethical minefield.